Colorectal cancer, Gastric cancer
Conditions
Interventions
None listed
Sponsors
TAIHO PHARMACEUTICAL CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Doctors: 1) Doctors in Japan 2) Those whose main area of expertise is either gastroenterology, clinical oncology, gastrointestinal surgery or general surgery * The main area of expertise is based on their self-reported information. 3) Those who work at a facility with 100 beds or more 4) Those who administered trifluridine/tipiracil to two or more patients with metastaticcolorectal cancer/ gastric cancer in the past year as a primary doctor 5) Those whose consent to participation in the study is obtained Patients: 1) Adults living in Japan 2) Patients with gastric or colorectal cancer 3) Those who have taken trifluridine/tipiracil for gastric or colorectal cancer 4) Those who have received more than two prescriptions for trifluridine/tipiracil 5) Those whose last prescription for trifluridine/tipiracil was within the past six months 6) Those whose consent to participation in the study is expected to be obtained
Exclusion criteria
Exclusion criteria: Doctors: 1) Doctors who are external research advisors in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The state of occurrence of adverse effects of trifluridine/tipiracil and the details of supportive care | — |
Countries
Japan
Contacts
Public ContactHaruhiko Seki
INTAGE Healthcare Value & Access Department
Outcome results
None listed